Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (754) 754
science & technology (690) 690
life sciences & biomedicine (651) 651
male (516) 516
female (396) 396
animals (355) 355
dipeptides - therapeutic use (353) 353
dipeptides - adverse effects (348) 348
middle aged (296) 296
dipeptides - pharmacology (293) 293
adult (260) 260
biological and medical sciences (231) 231
dipeptides - administration & dosage (214) 214
adamantane - analogs & derivatives (211) 211
medical sciences (209) 209
aged (206) 206
diabetes mellitus, type 2 - drug therapy (173) 173
pharmacology & pharmacy (161) 161
rats (143) 143
treatment outcome (137) 137
double-blind method (134) 134
adamantane - therapeutic use (126) 126
abridged index medicus (125) 125
adamantane - adverse effects (124) 124
pharmacology. drug treatments (121) 121
mice (112) 112
saxagliptin (107) 107
dipeptidyl-peptidase iv inhibitors - therapeutic use (103) 103
type 2 diabetes (99) 99
endocrinology & metabolism (98) 98
dipeptidyl-peptidase iv inhibitors - adverse effects (91) 91
hypoglycemic agents - therapeutic use (88) 88
dose-response relationship, drug (86) 86
time factors (85) 85
analysis (81) 81
drug therapy, combination (78) 78
hypoglycemic agents - adverse effects (75) 75
diabetes (74) 74
aspartame - adverse effects (73) 73
dipeptides - metabolism (72) 72
enalapril (69) 69
care and treatment (68) 68
risk factors (66) 66
research (65) 65
dipeptides - pharmacokinetics (64) 64
hypertension - drug therapy (64) 64
drug therapy (61) 61
adamantane - administration & dosage (60) 60
dipeptides - chemistry (60) 60
disease models, animal (60) 60
peptides (59) 59
adolescent (57) 57
diabetes mellitus, type 2 - blood (55) 55
cardiovascular system & cardiology (53) 53
neurosciences (53) 53
neurosciences & neurology (53) 53
oncology (53) 53
general & internal medicine (52) 52
clinical trials (50) 50
lisinopril (49) 49
medicine & public health (49) 49
young adult (49) 49
health aspects (48) 48
hypoglycemic agents - administration & dosage (48) 48
administration, oral (47) 47
aged, 80 and over (47) 47
biochemistry & molecular biology (47) 47
medicine, general & internal (47) 47
clinical trials as topic (46) 46
cardiovascular system (44) 44
cell biology (44) 44
research article (44) 44
dosage and administration (43) 43
proteins (43) 43
blood glucose - drug effects (42) 42
blood glucose - metabolism (42) 42
blood pressure - drug effects (42) 42
dipeptides - blood (42) 42
medicine, research & experimental (42) 42
research & experimental medicine (42) 42
studies (42) 42
diabetes mellitus, type 2 - complications (41) 41
dipeptidyl-peptidase iv inhibitors - administration & dosage (41) 41
internal medicine (41) 41
cardiac & cardiovascular systems (39) 39
chemistry (39) 39
drug administration schedule (39) 39
glycated hemoglobin a - metabolism (39) 39
medicine (39) 39
neurology (39) 39
toxicology (39) 39
angiotensin-converting enzyme inhibitors (38) 38
cancer (37) 37
glucose (37) 37
metformin (37) 37
pharmacology/toxicology (37) 37
rats, wistar (37) 37
medical research (36) 36
metformin - administration & dosage (36) 36
mice, inbred c57bl (36) 36
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1006) 1006
Russian (22) 22
German (12) 12
Chinese (6) 6
French (6) 6
Japanese (5) 5
Danish (3) 3
Portuguese (3) 3
Italian (2) 2
Norwegian (2) 2
Spanish (2) 2
Swedish (2) 2
Czech (1) 1
Dutch (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: A retrospective cohort study
by Toh, Sengwee and Hampp, Christian and Reichman, Marsha E and Graham, David J and Balakrishnan, Suchitra and Pucino, Frank and Hamilton, Jack and Lendle, Samuel and Iyer, Aarthi and Rucker, Malcolm and Pimentel, Madelyn and Nathwani, Neesha and Griffin, Marie R and Brown, Nancy J and Fireman, Bruce H
Annals of internal medicine, ISSN 0003-4819, 06/2016, Volume 164, Issue 11, pp. 705 - 714
Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptides - adverse effects | Humans | Middle Aged | Risk Factors | Male | Hospitalization | Sulfonylurea Compounds - adverse effects | Thiazolidinediones - adverse effects | Female | Retrospective Studies | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Heart Failure - chemically induced | Adamantane - adverse effects | Adamantane - analogs & derivatives | Sitagliptin Phosphate - adverse effects | Heart failure | Complications and side effects | Hospital care | Sitagliptin | Forecasts and trends | Risk factors | Saxagliptin | Prescription drugs | Cardiology | Risk assessment | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
by Rosenstock, Julio and Hansen, Lars and Zee, Pamela and Li, Yan and Cook, William and Hirshberg, Boaz and Iqbal, Nayyar
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 376 - 383
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Benzhydryl Compounds - administration & dosage | Humans | Middle Aged | Male | Metformin - adverse effects | Benzhydryl Compounds - adverse effects | Urinary Tract Infections - chemically induced | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Drug Therapy, Combination | Hypoglycemia - chemically induced | Glucosides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Blood Glucose - drug effects | Dipeptides - administration & dosage | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Care and treatment | Usage | Analysis | Clinical trials | Dosage and administration | Glycemic index | Metformin | Saxagliptin | Drug therapy | Diabetes | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Randomized, Double-Blind, phase 3 trial of triple therapy with dapagliflozin Add-on to saxagliptin plus metformin in type 2 diabetes
by Mathieu, Chantal and Ranetti, Aurelian Emil and Li, Danshi and Ekholm, Ella and Cook, William and Hirshberg, Boaz and Chen, Hungta and Hansen, Lars and Iqbal, Nayyar
Diabetes care, ISSN 0149-5992, 11/2015, Volume 38, Issue 11, pp. 2009 - 2017
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemia - epidemiology | Metformin - therapeutic use | Benzhydryl Compounds - administration & dosage | Humans | Middle Aged | Male | Metformin - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - chemically induced | Adamantane - therapeutic use | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Hypoglycemia - chemically induced | Glucosides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Blood Glucose - drug effects | Dipeptides - administration & dosage | Urinary Tract Infections - epidemiology | Drug Therapy, Combination - methods | Glucosides - administration & dosage | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Treatment outcome | Usage | Safety and security measures | Dapagliflozin | Analysis | Clinical trials | Dosage and administration | Metformin | Saxagliptin | Prescription drugs | Diabetes | Comparative analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes
by Tkáč, Ivan and Raz, Itamar
Diabetes care, ISSN 0149-5992, 02/2017, Volume 40, Issue 2, pp. 284 - 286
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Sitagliptin Phosphate - administration & dosage | Acute Disease | Piperidines - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Pancreatitis - epidemiology | Dipeptides - adverse effects | Humans | Pancreatitis - chemically induced | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Incidence | Randomized Controlled Trials as Topic | Dipeptides - administration & dosage | Uracil - administration & dosage | Uracil - adverse effects | Piperidines - adverse effects | Adamantane - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Adamantane - adverse effects | Adamantane - analogs & derivatives | Sitagliptin Phosphate - adverse effects | Uracil - analogs & derivatives | Type 2 diabetes | Diabetics | Treatment outcome | Care and treatment | Analysis | Pancreatitis | Health aspects | Risk factors | Cardiovascular system | Clinical trials | Medical treatment | Risk assessment | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Drug-induced hypoglycaemia in type 2 diabetes
by Inkster, Berit and Zammitt, Nicola N and Frier, Brian M
Expert opinion on drug safety, ISSN 1474-0338, 07/2012, Volume 11, Issue 4, pp. 597 - 614
Type 2 diabetes | thiazolidinedione | sulphonylurea | hypoglycaemia | DPP-4 inhibitor | GLP-1 agonist | metformin | Hypoglycaemia | Sulphonylurea | Metformin | Thiazolidinedione | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Pharmacogenetics | Venoms - adverse effects | Dipeptides - adverse effects | Humans | Sulfonylurea Compounds - adverse effects | Thiazolidinediones - adverse effects | Metformin - adverse effects | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemia - chemically induced | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Index Medicus | Drugs | Enzymes | Side effects | Reviews | Antibiotics | Diabetes mellitus | Psychology | Risk factors | Stress
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?
by Clifton, Peter, MD, PhD
Clinical therapeutics, ISSN 0149-2918, 2014, Volume 36, Issue 12, pp. 2072 - 2079
Internal Medicine | Medical Education | DPP-IV inhibition | cardiovascular disease | heart failure | type 2 diabetes | Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) | Vildagliptin in Ventricular Dysfunction Diabetes Trial (VIVIDD) | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Cardiology. Vascular system | Heart | Diabetes. Impaired glucose tolerance | Pharmacology. Drug treatments | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Heart failure, cardiogenic pulmonary edema, cardiac enlargement | Coronary heart disease | Endocrine pancreas. Apud cells (diseases) | Dipeptides - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptides - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Pyrrolidines - adverse effects | Uracil - therapeutic use | Hospitalization | Pyrrolidines - therapeutic use | Uracil - adverse effects | Piperidines - therapeutic use | Piperidines - adverse effects | Adamantane - therapeutic use | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Heart Failure - chemically induced | Adamantane - adverse effects | Adamantane - analogs & derivatives | Nitriles - therapeutic use | Sitagliptin Phosphate - adverse effects | Uracil - analogs & derivatives | Heart failure | Regulatory agencies | Heart attacks | Peptides | Mortality | Cardiovascular disease | FDA approval | Patients | Studies | Databases | Diabetes | Drug therapy | Acute coronary syndromes | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development
by Viereck, Christopher and Boudes, Pol
Contemporary clinical trials, ISSN 1551-7144, 2011, Volume 32, Issue 3, pp. 324 - 332
Hematology, Oncology and Palliative Medicine | Cardiovascular | Saxagliptin and liraglutide | Sitagliptin | Alogliptin | Vildagliptin | Insulin inhalation powder | Exenatide | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Diabetes. Impaired glucose tolerance | General and cellular metabolism. Vitamins | Pharmacology. Drug treatments | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Triazoles - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | United States | Humans | Pyrrolidines - adverse effects | Allylamine - adverse effects | Randomized Controlled Trials as Topic - standards | Time Factors | Investigational New Drug Application - legislation & jurisprudence | Sitagliptin Phosphate | Incretins - chemistry | Colesevelam Hydrochloride | Incretins - physiology | United States Food and Drug Administration | Adamantane - adverse effects | Adamantane - analogs & derivatives | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Dipeptides - adverse effects | Allylamine - analogs & derivatives | Uracil - adverse effects | Piperidines - adverse effects | Pyrazines - adverse effects | Cardiovascular Diseases - chemically induced | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Liraglutide | Peptides - adverse effects | Practice Guidelines as Topic | Uracil - analogs & derivatives | Type 2 diabetes | Hypoglycemic agents | Drug therapy | Cardiovascular diseases | Drug approval | Risk factors | Diabetes therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
by Scirica, Benjamin M and Bhatt, Deepak L and Braunwald, Eugene and Steg, P. Gabriel and Davidson, Jaime and Hirshberg, Boaz and Ohman, Peter and Frederich, Robert and Wiviott, Stephen D and Hoffman, Elaine B and Cavender, Matthew A and Udell, Jacob A and Desai, Nihar R and Mosenzon, Ofri and McGuire, Darren K and Ray, Kausik K and Leiter, Lawrence A and Raz, Itamar and Savor-Timi Steering Comm Investig and SAVOR-TIMI 53 Steering Committee and Investigators
The New England journal of medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1317 - 1326
no | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Adamantane - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Hypoglycemia - chemically induced | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Dipeptides - therapeutic use | Double-Blind Method | Pancreatitis - epidemiology | Dipeptides - adverse effects | Kaplan-Meier Estimate | Pancreatitis - chemically induced | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy | Heart diseases | Risk factors | Saxagliptin | Myocardial infarction | Cerebral infarction | Heart attacks | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Patients | Heart rate | Ischemia | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Clinical practice considerations and review of the literature for the use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease
by Ramirez, German and Morrison, Anthony and Bittle, Polly
Endocrine practice, ISSN 1530-891X, 11/2013, Volume 19, Issue 6, pp. 1025 - 1034
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Triazoles - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Pyrrolidines - adverse effects | Pyrazines - metabolism | Pyrazines - therapeutic use | Renal Insufficiency, Chronic - complications | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Pyrrolidines - therapeutic use | Renal Insufficiency, Chronic - drug therapy | Renal Insufficiency, Chronic - metabolism | Quinazolines - metabolism | Pyrrolidines - metabolism | Adamantane - therapeutic use | Linagliptin | Purines - adverse effects | Purines - therapeutic use | Dipeptides - metabolism | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Nitriles - metabolism | Dipeptides - therapeutic use | Piperidines - metabolism | Purines - metabolism | Adamantane - metabolism | Dipeptides - adverse effects | Uracil - therapeutic use | Triazoles - metabolism | Uracil - adverse effects | Piperidines - therapeutic use | Quinazolines - therapeutic use | Piperidines - adverse effects | Pyrazines - adverse effects | Quinazolines - adverse effects | Uracil - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Nitriles - therapeutic use | Uracil - analogs & derivatives
Journal Article
Details down arrow
10. Full Text Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes
by Matthaei, Stephan and Catrinoiu, Doina and Celinski, Aleksander and Ekholm, Ella and Cook, William and Hirshberg, Boaz and Chen, Hungta and Iqbal, Nayyar and Hansen, Lars
Diabetes care, ISSN 0149-5992, 11/2015, Volume 38, Issue 11, pp. 2018 - 2024
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemia - epidemiology | Benzhydryl Compounds - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Metformin - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Hypoglycemia - chemically induced | Glucosides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Blood Glucose - drug effects | Dipeptides - administration & dosage | Drug Therapy, Combination - methods | Glucosides - administration & dosage | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Treatment outcome | Usage | Dapagliflozin | Analysis | Clinical trials | Dosage and administration | Metformin | Drug therapy | Saxagliptin | Hemoglobin | Prescription drugs | Diabetes | Safety | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights